These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36607429)

  • 1. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.
    Lordick F; Thuss-Patience P; Bitzer M; Maurus D; Sahin U; Türeci Ö
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5937-5950. PubMed ID: 36607429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
    Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
    Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
    Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
    Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
    J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
    Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
    Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Kawazoe A; Hirakawa A; Nakanishi Y; Furuki S; Fukuda M; Ueno Y; Raizer J; Arozullah A
    Cancer Sci; 2023 Apr; 114(4):1606-1615. PubMed ID: 36478334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
    de Moraes FCA; Pasqualotto E; Chavez MP; Ferreira ROM; De Castria TB; Burbano RMR
    BMC Cancer; 2024 Feb; 24(1):240. PubMed ID: 38383390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.
    Lordick F; Van Cutsem E; Shitara K; Xu RH; Ajani JA; Shah MA; Oh M; Ganguli A; Chang L; Rhoten S; Bhattacharya P; Matsangou M; Park JW; Pophale R; Ranganath R; Kang YK
    ESMO Open; 2024 Aug; 9(8):103663. PubMed ID: 39146670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zolbetuximab: First Approval.
    Keam SJ
    Drugs; 2024 Aug; 84(8):977-983. PubMed ID: 38967717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of zolbetuximab in pancreatic cancer models.
    Türeci Ӧ; Mitnacht-Kraus R; Wöll S; Yamada T; Sahin U
    Oncoimmunology; 2019; 8(1):e1523096. PubMed ID: 30546962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
    Sahin U; Schuler M; Richly H; Bauer S; Krilova A; Dechow T; Jerling M; Utsch M; Rohde C; Dhaene K; Huber C; Türeci Ö
    Eur J Cancer; 2018 Sep; 100():17-26. PubMed ID: 29936063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
    Lai S; Luo S; Huang Q; Lin S; Huang X; Xue H; Cai Y; Xu X; Weng X
    Pharmacogenomics; 2024; 25(5-6):249-257. PubMed ID: 38884946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
    Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Van Cutsem E; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
    Future Oncol; 2024; 20(26):1861-1877. PubMed ID: 38861294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Xu RH; Ajani JA; Moran D; Guerrero A; Li R; Pavese J; Matsangou M; Bhattacharya P; Ueno Y; Wang X; Shah MA
    Gastric Cancer; 2024 Sep; 27(5):1058-1068. PubMed ID: 38954176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials.
    Liang Z; Liu L; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
    Front Oncol; 2023; 13():1258347. PubMed ID: 37886169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
    Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
    Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
    Kubota Y; Shitara K
    Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
    Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
    Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
    Lordick F; Al-Batran SE; Ganguli A; Morlock R; Sahin U; Türeci Ö
    Gastric Cancer; 2021 May; 24(3):721-730. PubMed ID: 33755863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.